Spratt DE - Search Results

1

Identification and Validation of the Prognostic Impact of Metastatic Prostate Cancer Phenotypes.

Labe SA, Wang X, Lehrer EJ, Kishan AU, Spratt DE, Lin C, Morgans AK, Ponsky L, Garcia JA, Garrett S, Wang M, Zaorsky NG. Labe SA, et al. Among authors: spratt de. Clin Genitourin Cancer. 2022 Aug;20(4):371-380. doi: 10.1016/j.clgc.2022.02.008. Epub 2022 Feb 24. Clin Genitourin Cancer. 2022. PMID: 35383004 Free PMC article.

2

Prognostic importance of Gleason 7 disease among patients treated with external beam radiation therapy for prostate cancer: results of a detailed biopsy core analysis.

Spratt DE, Zumsteg Z, Ghadjar P, Pangasa M, Pei X, Fine SW, Yamada Y, Kollmeier M, Zelefsky MJ. Spratt DE, et al. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1254-61. doi: 10.1016/j.ijrobp.2012.10.013. Epub 2012 Nov 20. Int J Radiat Oncol Biol Phys. 2013. PMID: 23182392

3

Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer.

Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Kollmeier M, McBride S, Yamada Y, Zelefsky MJ. Zumsteg ZS, et al. Among authors: spratt de. J Urol. 2015 Dec;194(6):1624-30. doi: 10.1016/j.juro.2015.06.100. Epub 2015 Jul 10. J Urol. 2015. PMID: 26165583 Free PMC article.

4

Independent surgical validation of the new prostate cancer grade-grouping system.

Spratt DE, Cole AI, Palapattu GS, Weizer AZ, Jackson WC, Montgomery JS, Dess RT, Zhao SG, Lee JY, Wu A, Kunju LP, Talmich E, Miller DC, Hollenbeck BK, Tomlins SA, Feng FY, Mehra R, Morgan TM. Spratt DE, et al. BJU Int. 2016 Nov;118(5):763-769. doi: 10.1111/bju.13488. Epub 2016 Apr 19. BJU Int. 2016. PMID: 27009882 Free article.

5

Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease.

Spratt DE, Osborne JR, Zumsteg ZS, Rebeiz K, Leeman J, Rivera A, Morris MJ, Zelefsky MJ. Spratt DE, et al. Prostate Cancer Prostatic Dis. 2016 Sep;19(3):271-6. doi: 10.1038/pcan.2016.14. Epub 2016 Apr 26. Prostate Cancer Prostatic Dis. 2016. PMID: 27112529

6

Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up.

Spratt DE, Jackson WC, Abugharib A, Tomlins SA, Dess RT, Soni PD, Lee JY, Zhao SG, Cole AI, Zumsteg ZS, Sandler H, Hamstra D, Hearn JW, Palapattu G, Mehra R, Morgan TM, Feng FY. Spratt DE, et al. Prostate Cancer Prostatic Dis. 2016 Sep;19(3):292-7. doi: 10.1038/pcan.2016.18. Epub 2016 May 24. Prostate Cancer Prostatic Dis. 2016. PMID: 27215611

7

Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis.

Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL, Feng FY. Zhao SG, et al. Among authors: spratt de. Lancet Oncol. 2016 Nov;17(11):1612-1620. doi: 10.1016/S1470-2045(16)30491-0. Epub 2016 Oct 12. Lancet Oncol. 2016. PMID: 27743920

8

Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.

Dess RT, Jackson WC, Suy S, Soni PD, Lee JY, Abugharib AE, Zumsteg ZS, Feng FY, Hamstra DA, Collins SP, Spratt DE. Dess RT, et al. Among authors: spratt de. Cancer. 2017 May 1;123(9):1635-1642. doi: 10.1002/cncr.30519. Epub 2016 Dec 21. Cancer. 2017. PMID: 28001303 Free article.

9

National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer.

Yang DD, Muralidhar V, Mahal BA, Labe SA, Nezolosky MD, Vastola ME, King MT, Martin NE, Orio PF 3rd, Choueiri TK, Trinh QD, Spratt DE, Hoffman KE, Feng FY, Nguyen PL. Yang DD, et al. Among authors: spratt de. Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):338-343. doi: 10.1016/j.ijrobp.2017.02.020. Epub 2017 Feb 21. Int J Radiat Oncol Biol Phys. 2017. PMID: 28463152

10

Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer.

Zumsteg ZS, Zelefsky MJ, Woo KM, Spratt DE, Kollmeier MA, McBride S, Pei X, Sandler HM, Zhang Z. Zumsteg ZS, et al. Among authors: spratt de. BJU Int. 2017 Nov;120(5B):E87-E95. doi: 10.1111/bju.13903. Epub 2017 Jun 3. BJU Int. 2017. PMID: 28464446 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

501 results

Search Page

Filters